The IL-1 family and inflammatory diseases

Clinical and Experimental Rheumatology

Volumn 20, Issue 5 SUPPL. 27, 2002, Pages

  Dinarello, C A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Binding proteins; Cytokines; Rheumatoid arthritis

Indexed keywords

ANGIOGENIC FACTOR; BINDING PROTEIN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYTOKINE; GAMMA INTERFERON; HEMOPOIETIC GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BLOOD VESSEL; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL STIMULATION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; EXPOSURE; EXTRAVASCULAR SPACE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN GENOME; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE; MESENCHYME CELL; NONHUMAN; PANNUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-18; ISOENZYMES; LIGANDS; MEMBRANE PROTEINS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, INTERLEUKIN-1;

EID: 0036398446     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (110)

1. CUNNANE G, MADIGAN A, MURPHY E, FITZ-GERALD O, BRESNIHAN B: The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40; 62-9.
2. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
3. BRESNIHAN B, NEWMARK RD, ROBBINS S, McCABE DP, GENANT HK: Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. Arthritis Rheum 2000; 43 (Suppl. 9): S289.
4. RECTENWALD JE, MOLDAWER LL, HUBER TS, SEEGER JM, OZAKI CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000; 102: 1697-702.
5. DINARELLO CA, CANNON JG, WOLFF SM, et al.: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163; 1433-50.
6. PROBERT L, PLOWS D, KONTOGEORGOS G, KOLLIAS G: The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995; 25: 1794-7.
7. WATANABE N, KAWAGUCHI M, KOBAYASHI Y: Activation of interleukin-1b converting enzyme by nigericin is independent of apoptosis. Cytokine 1998; 10: 645-53.
8. COESHOTT C, OHNEMUS C, PILYAVSKAYA A, et al.: Converting enzyme-independent release of TNFα and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc Natl Acad Sci USA 1999; 96: 6261-6.
9. HORAI R, SAIJO S, TANIOKA H, et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
10. NICKLIN MJ, HUGHES DE, BARTON JL, URE JM, DUFF GW: Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191: 303-12.
11. AURON PE, WEBB AC, ROSENWASSER LJ, et al.: Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81: 7907-11.
12. LOMEDICO PT, GUBLER R, HELLMANN CP, et al.: Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312: 458-62.
13. MULERO JJ, PACE AM, NELKEN ST, et al.: IL1HY1: A novel interleukin-1 receptor antagonist gene. Biochem Biophys Res Commun 1999; 263: 702-6.
14. BUSFIELD SJ, COMRACK CA, YU G, et al.: Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 2000; 66: 213-6.
15. BARTON JL, HERBST R, BOSISIO D, HIGGINS L, NICKLIN MJ: A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur J Immunol 2000; 30: 3299-308.
16. PAN G, RISSER P, MAO W, et al.: IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001; 13: 1-7.
17. KUMAR S, MCDONNELL PC, LEHR R, et al.: Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000; 275: 10308-14.
18. LIN H, HO AS, HALEY-VICENTE D, et al.: Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001; 276: 20597-602.
19. COLOTTA F, DOWER SK, SIMS JE, MANTOVANI A: The type II "decoy" receptor: a novel regulatory pathway for interleukin-1. Immunol Today 1994; 15: 562-6.
20. NOVICK D, KIM S-H, FANTUZZI G, REZNIKOV L, DINARELLO CA, RUBINSTEIN M: Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127-36.
21. GAYLE MA, SLACK JL, BONNERT TP, et al.: Cloning of a putative ligand for the T1/ST2 receptor. J Biol Chem 1996; 271: 5784-9.
22. MORITZ D, RODEWALD H-R, GHEYSELINCK J, KLEMENZ R: The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells an on fetal blood mast cell progenitors. J. Immunol. 1998; 161: 4866-74.
23. PARNET P, GARKA KE, BONNERT TP, DOWER SK, SIMS JE: IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem 1996; 271: 3967-70.
24. TORIGOE K, USHIO S, OKURA T, et al.: Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997; 272: 25737-42.
25. DEBETS R, TIMANS JC, HOMEY B, et al.: Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 2001; 167: 1440-6.
26. BORN TL, THOMASSEN E, BIRD TA, SIMS JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998; 273: 29445-50.
27. KIM SH, REZNIKOV LL, STUYT RJ, et al.: Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain. J Immunol 2001; 166: 148-54.
28. SANA TR, DEBETS R, TIMANS JC, BAZAN JF, KASTELEIN RA: Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. Genomics 2000; 69: 252-62.
29. CARRIE A, JUN L, BIENVENU T, et al.: A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Nat Genet 1999; 23: 25-31.
30. SYMONS JA, EASTGATE JA, DUFF GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 1991; 174: 1251-4.
31. SYMONS JA, YOUNG PA, DUFF GW: The soluble interleukin-1 receptor: ligand binding properties and mechanisms of release. Lymphokine Cytokine Res 1999; 12: 381.
32. SCAPIGLIATI G, GHIARA P, BARTALINI A, TAGLIBUE A, BORASCHI D: Differential binding of IL-1α and IL-1β to receptors on B and T cells. FEBS Lett 1989; 243: 394-8.
33. GHIARA P, ARMELLINI D, SCAPIGLIATI G, et al.: Biological role of the IL-1 receptor type II as defined by a monoclonal antibody. Cytokine 1991; 3: 473 (abs).
34. MCMAHON CJ, SLACK JL, MOSLEY B, et al.: A novel IL-1 receptor cloned form B cells by mammalian expression is expressed in many cell types. EMBO J 1991; 10: 2821-32.
35. COLOTTA F, RE F, MUZIO M, et al.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472-5.
36. ALCAMI A, SMITH GL. (1992) A soluble receptor for interleukin-1β encoded by vaccinia virus: A novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167.
37. SPRIGGS MK, HRUBY DE, MALISZEWSKI CR, et al.: Vaccinia and cowpox viruses encode a novel secreted interleukin-1 binding protein. Cell 1992; 71: 145-52.
38. DOWER SK, FANSLOW W, JACOBS C, WAUGH S, SIMS JE, WIDMER MB: Interleukin-1 antagonists. Therapeutic Immunol 1994; 1: 113-22.
39. BRISTULF J, GATTI S, MALINOWSKY D, BJORK L, SUNDGREN AK, BARTFAI T: Interleukin-1 stimulates the expression of type I and type II interleukin-1 receptors in the rat insulinoma cell line Rinm5F; sequencing a rat type II interleukin-1 receptor cDNA. Eup Cyokine Netw 1994; 5: 319-30.
40. AREND WP, MALYAK M, SMITH MF, et al.: Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994; 153: 4766-74.
41. SIMS JE, GIRI JG, DOWER SK: The two interleukin-1 receptors play different roles in IL-1 activities. Clin Immunol Immunopathol 1994; 72: 9-14.
42. SYMONS JA, YOUNG PA, DUFF GW: Differential release and ligand binding of type II IL-1 receptors. Cytokine 1994; 6: 555 (abs).
43. LANG D, KNOP J, WESCHE H, et al.: The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998; 161: 6871-7.
44. NEUMANN D, KOLLEWE C, MARTIN MU, BORASCHI D: The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 2000; 165: 3350-7.
45. PERREGAUX D, BARBERIA J, LANZETTI AJ, GEOGHEGAN KF, CARTY TJ, GABEL CA: IL-1β maturation: evidence that maturre cytokine formation can be induced specifically by nigercin. J Immunol 1992; 149: 1294-303.
46. THOMPSON GJ, LANGLAIS C, CAIN K, CONLEY EC, COHEN GM: Elevated extracellular K inhibits death-receptor and chemical-mediated apoptosis prior to caspase activation and cytochrome c release. Biochem J 2001; 357: 137-45.
47. MAIER JAM, VOULALAS P, ROEDER D, MACIAG T: Extension of the life span of human endothelial cells by an interleukin-1α anti-sense oligomer. Science 1990; 249: 1570-4.
48. MAIER JAM, STATUTO M, RAGNOTTI G: Endogenous interleukin-1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 1994; 14: 1845-51.
49. HORAI R, ASANO M, SUDO K, et al.: Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998; 187: 1463-75.
50. HAMMERBERG C, AREND WP, FISHER GJ, et al.: Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992; 90: 571-83.
51. KURT-JONES EA, BELLER DI, MIZEL SB, UNANUE ER: Identification of a membrane-associated interieukin-1 in macrophages. Proc Natl Acad Sci USA 1985; 82: 1204-8.
52. BRODY DT, DURUM SK: Membrane IL-1: IL-1α, precursor binds to the plasma membrane via a lectin-like interaction. J Immunol 1989; 143: 1183.
53. KAPLANSKI G, FARNARIER C, KAPLANSKI S, et al.: Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 1994; 84: 4242-8.
54. VAN DEN BERG WB: Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001; 30:7-16.
55. ZHENG H, FLETCHER D, KOZAK W, et al.: Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity 1995; 3: 9-19.
56. FANTUZZI G, KU G, HARDING MW, et al.: Response to local inflammation of IL-1β converting enzyme-deficient mice. J Immunol 1997; 158: 1818-24.
57. FANTUZZI G, SACCO S, GHEZZI P, DINARELLO CA: Physiological and cytokine responses in interleukin-1β-deficient mice after zymosan-induced inflammation. Am J Physiol 1997; 273: R400-6.
58. ALHEIM K, CHAI Z, FANTUZZI G, et al.: Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. Proc Natl Acad Sci USA 1997; 94: 2681-6.
59. FANTUZZI G, ZHENG H, FAGGIONI R, et al.: Effect of endotoxin in IL-1β-deficient mice. J Immunol 1996; 157: 291-6.
60. FAGGIONI R, FANTUZZI G, FULLER J, DINARELLO CA, FEINGOLD KR, GRUNFELD C: IL-1β mediates leptin induction during inflammation. Am J Physiol 1998; 274: R204-8.
61. REZNIKOV LL, SHAMES BD, BARTON HA, et al.: Interleukin-1β-deficiency results in reduced NF-kB levels in pregnant mice. Am J Physiol 2000; 278: R263-70.
62. KOZAK W, KLUGER MJ, SOSZYNSKI D, et al.: IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci 1998; 856: 33-47.
63. KUIDA K, LIPPKE JA, KU G, et al.: Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science 1995; 267: 2000-3.
64. NAKAE S, ASANO M, HORAI R, IWAKURA Y: Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production. Immunology 2001; 104: 402-9.
65. LABOW M, SHUSTER D, ZETTERSTROM M, et al.: Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997; 159: 2452-61.
66. HIRSCH E, IRIKURA VM, PAUL SM, HIRSH D: Functions of interleukin-1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci (USA) 1996; 93; 11008-13.
67. JOSEPHS MD, SOLORZANO CC, TAYLOR M, et al.: Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra. Am J Physiol Regul Integr Comp Physiol 2000; 278: R824-30.
68. ABBONDANZO SJ, CULLINAN EB, MCINTYRE K, LABOW MA, STEWART CL: Reproduction in mice lacking a functional type 1 IL-1 receptor. Endocrinology 1996; 137: 3598-601.
69. VARGAS SJ, NAPRTA A, GLACCUM M, LEE SK, KALINOWSKI J, LORENZO JA: Interleukin-6 expression and histomorphometry of bones from mice deficient in receptors for interleukin-1 or tumor necrosis factor. J Bone Miner Res 1996; 11: 1736-44.
70. MAN MQ, WOOD L, ELIAS PM, FEINGOLD KR: Cutaneous barrier repair and pathophysiology following barrier disruption in IL-1 and TNF type I receptor deficient mice. Exp Dermatol 1999; 8: 261-6.
71. CULLINAN EB, KWEE L, NUNES P, et al.: IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998; 161: 5614-20.
72. ROSENBAUM JT, HAN YB, PARK JM, KENNEDY M, PLANCK SR: Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice. J Rheumatol 1998; 25: 2408-16.
73. SHORNICK LP, DE TOGNI P, MARIATHASAN S, et al.: Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitro-chlorobenzone. J Exp Med 1996; 183: 1427-36.
74. LORENZO JE, NAPRTA A, RAO Y, et al.: Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinol 1998; 139: 3022-5.
75. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM, et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825-32.
76. NAKAMURA K, OKAMURA H, WADA M, NAGATA K, TAMURA T: Endotoxin-induced serum factor that stimulates gamma inteferon production. Infect Immun 1989; 57: 590-5.
77. OKAMURA H, NAGATA K, KOMATSU T, et al.: A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995; 63: 3966-72.
78. GU Y, KUIDA K, TSUTSUI H, et al.: Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997; 275: 206-9.
79. GHAYUR T, BANERJEE S, HUGUNIN M, et al.: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619-23.
80. OKAMURA H, TSUTSUI H, KOMATSU T, et al.: Cloning of a new cytokine that induces interferon-γ. Nature 1995; 378: 88-91.
81. NETEA MG, FANTUZZI G, KULLBERG BJ, et al.: Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 2000; 164: 2644-9.
82. YOSHIMOTO T, TAKEDA K, TANAKA T, et al.: IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFNγ production. J Immunol 1998; 161: 3400-7.
83. KIM S-H, EISENSTEIN M, REZNIKOV L, et al.: Structural requirements of six naturally occurring isoforms of the interleukin-18 binding protein to inhibit interleukin-18. Proc Natl Acad Sci USA 2000; 97:1190-5.
84. KIM SH, AZAM T, YOON DY, et al.: Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc Natl Acad Sci U S A 2001; 98: 3304-9.
85. NOVICK D, SCHWARTSBURD B, PINKUS R, et al.: A novel IL-18BP ELISA shows elevated serum il-18bp in sepsis and extensive decrease of free IL-18. Cytokine 2001; 14: 334-42.
86. JOOSTEN LA, VAN DE LOO FA, LUBBERTS E, et al.: An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol 2000; 165: 6553-8.
87. GRACIE JA, FORSEY RJ, CHAN WL, et al.: A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393-401.
88. WEI XQ, LEUNG BP, ARTHUR HM, MCINNES IB, LIEW FY: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166: 517-21.
89. PIZARRO TT, MICHIE MH, BENTZ M, et al.: IL-18, 9 novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999; 162: 6829-35.
90. KANAI T, WATANABE M, OKAZAWA A, SATO T, HIBI T: Interleukin-18 and Crohn's disease. Digestion 2001; 63: 37-42.
91. MONTELEONE G, TRAPASSO F, PARRELLO T, et al.: Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163: 143-7.
92. PAGES F, BERGER A, LEBEL-BINAY S, et al.: Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett 2000; 75: 9-14.
93. SIEGMUND B, FANTUZZI G, RIEDER F, et al.: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-γ production. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1264-73.
94. TEN HOVE T, CORBAZ A, AMITAI H, et al.: Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001; 121: 1372-9.
95. CHIKANO S, SAWADA K, SHIMOYAMA T, et al.: IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 2000; 47: 779-86.
96. WIRTZ S, BECKER C, BLUMBERG R, GALLE PR, NEURATH MF: Treatment of T Cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J Immunol 2002; 168: 411-20.
97. SIEGMUND B, LEHR HA, FANTUZZI G, DINARELLO CA: IL-1beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001; 98: 13249-54.
98. KUBOTA T, FANG J, BROWN RA, KRUEGER JM: Interleukin-18 promotes sleep in rabbits and rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R828-38.
99. GATTI S, BECK J, FANTUZZI G, BARTFAI T, DINARELLO CA: Effect of interleukin-18 on mouse core body temperature. Am J Physiol Regul Integr Comp Physiol 2002; 282: R702-9.
100. FURLAN R, MARTINO G, GALBIATI F, et al.: Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999; 163: 2403-9.
101. HORWITZ MS, EVANS CF, MCGAVERN DB, RODRIGUEZ M, OLDSTONE MB: Primary demyelination in transgenic mice expressing interferon-γ. Nat Med 1997; 3: 1037-41.
102. FAGGIONI R, JONES-CARSON J, REED DA, et al.: Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci USA 2000; 97: 2367-72.
103. TSUTSUI H, KAYAGAKI N, KUIDA K, et al.: Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999; 11: 359-67.
104. VIDAL-VANACLOCHA F, FANTUZZI G, MENDOZA L, et al.: IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000; 97: 734-9.
105. BOUTIN H, LEFEUVRE RA, HORAI R, ASANO M, IWAKURA Y, ROTHWELL NJ: Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001; 21: 5528-34.
106. HUANG D, SHI FD, GISCOMBE R, ZHOU Y, LJUNGGREN HG, LEFVERT AK: Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. Eur J Immunol 2001; 31: 225-32.
107. MIWA K, ASANO M, HORAI R, IWAKURA Y, NAGATA S, SUDA T: Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287-92.
108. PARSEY MV, KANEKO D, SHENKAR R, ABRAHAM E: Neutrophil apoptosis in the lung after hemorrhage or endotoxemia: apoptosis and migration are independent of IL-1beta. Clin Immunol 1999; 91: 219-25.
109. SEKI T, HEALY AM, FLETCHER DS, NOGUCHI T, GELEHRTER TD: IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury. Am J Physiol 1999; 277: G801-9.
110. SHORNICK LP, BISARYA AK, CHAPLIN DD: IL-1beta is essential for langerhans cell activation and antigen delivery to the lymph nodes during contact sensitization: evidence for a dermal source of IL-1beta. Cell Immunol 2001; 211: 105-12.